Logo do repositório
 
Publicação

Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025

2025-02-20Artigo científico Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas
datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg17:Parcerias para a Implementação dos Objetivos
dc.contributor.authorRose, Angela
dc.contributor.authorLucaccioni, Héloïse
dc.contributor.authorMarsh, Kimberly
dc.contributor.authorKirsebom, Freja
dc.contributor.authorWhitaker, Heather
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorBotnen, Amanda Bolt
dc.contributor.authorO’Doherty, Mark G.
dc.contributor.authorPozo, Francisco
dc.contributor.authorShahul Hameed, Safraj
dc.contributor.authorAndrews, Nick
dc.contributor.authorHamilton, Mark
dc.contributor.authorLauenborg Møller, Karina
dc.contributor.authorTrebbien, Ramona
dc.contributor.authorMarques, Diogo F.P.
dc.contributor.authorEuropean IVE group
dc.date.accessioned2026-01-14T15:45:57Z
dc.date.available2026-01-14T15:45:57Z
dc.date.issued2025-02-20
dc.description
dc.description.abstractThe 2024/25 influenza season in Europe is currently characterised by the co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness estimates from eight European studies conducted in 17 countries indicate an overall influenza A vaccine effectiveness of 32–53% in primary care settings and 33–56% in hospital settings, with some indications of lower effectiveness by subtype and higher effectiveness against influenza B (≥58% across settings). Where feasible, influenza vaccination should be encouraged and other preventive measures strengthened.eng
dc.description.sponsorshipThe EU-H study and EU-PC received funding from the European Centre for Disease Prevention and Control under framework contract ECDC/2021/016 and ECDC/2021/019, respectively. Aukse Mickiene has received a grant for the Independentn Investigator Initiated Research (Project Code/PO/Tracking Number WI236259; Grant ID#53233947); Pfizer R&D Investigator-Initiated Research program (https://www. pfizer.com/science/collaboration/investigator-initiated-research) for the scientific project “A prospective study on the long-term outcome and pathogenesis of tick-borne encephalitis”, and a Grant from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infectious Diseases of the Brain (ESGIB); sponsorship for participation in the international scientific conferences by MSD, Pfizer, Abbvie, Janssen, payments for lectures in local scientific conferences and consultation fees from GSK, Sanofi, Pfizer, E-visit. Ligita Jancoriene has received honoraria fees for lectures from Pfizer, Viatris, Swixx Biopharma.
dc.identifier.citationEuro Surveill. 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. Erratum in: Euro Surveill. 2025 Mar;30(11). doi: 10.2807/1560-7917.ES.2025.30.11.240320c
dc.identifier.doi10.2807/1560-7917.ES.2025.30.7.2500102
dc.identifier.eissn1025-496X
dc.identifier.issn1560-7917
dc.identifier.pmid39980423
dc.identifier.urihttp://hdl.handle.net/10400.18/10696
dc.language.isoeng
dc.peerreviewedyes
dc.publisherEuropean Centre for Disease Prevention and Control
dc.relation.hasversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.7.2500102
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectInfluenza
dc.subjectVaccine
dc.subjectEffectiveness
dc.subject2024-2025
dc.subjectEurope
dc.subjectDeterminantes da Saúde e da Doença
dc.subjectInfecções Respiratórias
dc.titleInterim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025eng
dc.typejournal article
dcterms.referenceshttps://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/30/7/25-00102_ROSE_Supplement.pdf?itemId=%2Fcontent%2Fsuppdata%2F10.2807%2F1560-7917.ES.2025.30.7.2500102-1&mimeType=pdf
dspace.entity.typePublication
oaire.citation.issue7
oaire.citation.startPage2500102
oaire.citation.titleEurosurveillance: Europe's journal on infectious disease surveillance, epidemiology, prevention and control
oaire.citation.volume30
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
eurosurv-30-7-2.pdf
Tamanho:
809.84 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais